Adenosine
Product Images NDC 51662-1345

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Adenosine (NDC 51662-1345). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carton (20 mL Carton)

This is a description of a medicine called Adenosine Injection, USP. The label contains information about the medication including dosage, storage details, and usage instructions. It comes in a 20mL single-dose vial labeled with a 2D barcode containing detailed batch information. The medication is intended for intravenous use only and should not be refrigerated to avoid crystallization. The label warns of the potential for crystallization and advises on how to dissolve any crystals that may occur. The medication must be used before its expiry date and any unused portion should be discarded.*

FDA Label Image

Adverse Reactions 3 (Adverse Reaction 3)

This text provides a list of potential disorders related to cardiac, gastrointestinal, general, immune system, nervous system, and respiratory issues that can arise from the administration of a medication or treatment. The listed disorders include cardiac arrest, atrial fibrillation, myocardial infarction, nausea, vomiting, chest pain, hypersensitivity, seizure activity, respiratory arrest, and more.*

FDA Label Image

Adverse Reactions 1 (Adverse Reactions 1)

Adenosine Injection may cause adverse reactions in patients. Based on a study involving 1,421 patients, the most common reactions reported were flushing, dyspnea, chest discomfort, headache, throat/neck/jaw discomfort, gastrointestinal discomfort, lightheadedness/dizziness, upper extremity discomfort, ST segment depression, first-degree AV block, second-degree AV block, paresthesia, hypotension, nervousness or arrhythmias.*

FDA Label Image

Adverse Reactions 2 (Adverse Reactions 2)

This description suggests that the text describes a list of symptoms and conditions that a patient might experience in various systems of the body. The symptoms listed include back and lower extremity discomfort, weakness, various cardiac problems like myocardial infarction and bradycardia, respiratory symptoms like cough, nervous system symptoms like drowsiness and tremors, and other symptoms in the genital/urinary system and special senses like blurred vision or nasal congestion.*

FDA Label Image

D And A (D And A)

This appears to be a table showing data on the patient infusion rate, with the first column indicating weight in kilograms and the second column indicating the corresponding milliliters per minute over a duration of 6 minutes for a total dose of 0.84 milligrams per kilogram. It is possible that this information is related to medication dosage or administration.*

FDA Label Image

Logo (Logo)

FDA Label Image

Serialized Labeling (Serialized Product)

FDA Label Image

Structure (Structure)

FDA Label Image

Vial Label (Vial Label)

This is a description for a single-dose vial of Adenosine Injection, containing 60mg/20mL of Adenosine in a sterile solution for intravenous infusion only. The solution must be clear at the time of use, and the vial does not contain any preservatives. This product should be stored at controlled room temperature between 20-25°C (68-77°F), and not refrigerated to prevent crystallization. The usual dosage instructions can be found in the package insert provided. This product was manufactured by Gland Pharma Limited, Hyderabad, India and is distributed in the USA by Hospira Inc., Lake Forest, IL. The expiration date is not available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.